Managers / Q4 2022 · view latest →
Alerce Investment Management, L.P.
CIK 0001844002 · 676 N. MICHIGAN AVENUE, SUITE 4000, CHICAGO, IL, 60611 · (312) 448-5500
Summary
Alerce Investment Management, L.P. reported $87M in U.S.-listed holdings across 6 positions for Q4 2022.
The portfolio is heavily concentrated: American Well alone accounts for 34.1% of reported value.
Compared with Q3 2022, the fund opened 1 new position and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 62.6% · $54M
- Other · 37.4% · $33M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| RNTXAILERON THERAPEUTICS INC | NEW | +830.5K | 830.5K | +$2M | $2M |
| AKBAAKEBIA THERAPEUTICS INC | ADDED | +10.44M | 15.09M | +$7M | $9M |
| GBTUSDGLOBAL BLOOD THERAPEUTICS IN | SOLD OUT | −356.3K | 0 | −$24M | $0 |
| ALRNEURAILERON THERAPEUTICS INC | SOLD OUT | −16.61M | 0 | −$3M | $0 |
| AMERICAN WELL CORP | ADDED | +3.37M | 10.48M | +$4M | $30M |
| WHWKAADI BIOSCIENCE INC | ADDED | +336.0K | 1.63M | +$3M | $21M |
| ANNXANNEXON INC | HELD | +0 | 4.41M | −$4M | $23M |
| ASSEMBLY BIOSCIENCES INC | HELD | +0 | 2.23M | −$757,250 | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | AMERICAN WELL CORP | CL A | 34.10% | $30M | 10.48M |
| 2 | ANNXANNEXON INChistory → | COM | 26.22% | $23M | 4.41M |
| 3 | WHWKAADI BIOSCIENCE INChistory → | COM | 24.07% | $21M | 1.63M |
| 4 | AKBAAKEBIA THERAPEUTICS INChistory → | COM | 10.02% | $9M | 15.09M |
| 5 | ASSEMBLY BIOSCIENCES INC | COM | 3.33% | $3M | 2.23M |
| 6 | RNTXAILERON THERAPEUTICS INChistory → | COM NEW | 2.26% | $2M | 830.5K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2024 | $57M | 5 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $62M | 5 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $51M | 5 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $95M | 5 | May 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $75M | 5 | Feb 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $59M | 6 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $77M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $76M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $87M | 6 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $104M | 7 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $54M | 7 | Aug 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $59M | 7 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $98M | 7 | Feb 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $146M | 7 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $184M | 7 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $226M | 7 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $254M | 7 | Feb 11, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.